Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Int J Obes (Lond) ; 43(4): 933-937, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-29795467

RESUMEN

Obesity increases risk of falling, but the effect of bariatric surgery on fall-related injuries is unknown. The aim of this study was therefore to study the association between bariatric surgery and long-term incidence of fall-related injuries in the prospective, controlled Swedish Obese Subjects study. At inclusion, body mass index was ≥ 34 kg/m2 in men and ≥38 kg/m2 in women. The surgery per-protocol group (n = 2007) underwent gastric bypass (n = 266), banding (n = 376), or vertical banded gastroplasty (n = 1365), and controls (n = 2040) received usual care. At the time of analysis (31 December 2013), median follow-up was 19 years (maximal 26 years). Fall-related injuries requiring hospital treatment were captured using data from the Swedish National Patient Register. During follow-up, there were 617 first-time fall-related injuries in the surgery group and 513 in the control group (adjusted hazard ratio 1.21, 95% CI, 1.07-1.36; P = 0.002). The incidence differed between treatment groups (P < 0.001, log-rank test) and was higher after gastric bypass than after usual care, banding and vertical banded gastroplasty (adjusted hazard ratio 0.50-0.52, P < 0.001 for all three comparisons). In conclusion, gastric bypass surgery was associated with increased risk of serious fall-related injury requiring hospital treatment.


Asunto(s)
Accidentes por Caídas/estadística & datos numéricos , Derivación Gástrica/efectos adversos , Obesidad Mórbida/cirugía , Accidentes por Caídas/prevención & control , Adulto , Femenino , Estudios de Seguimiento , Humanos , Masculino , Obesidad Mórbida/fisiopatología , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Suecia/epidemiología , Resultado del Tratamiento
2.
Neuropharmacology ; 79: 498-505, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24373901

RESUMEN

The central ghrelin signaling system engages key pathways of importance for feeding control, recently shown to include those engaged in anxiety-like behavior in rodents. Here we sought to determine whether ghrelin impacts on the central serotonin system, which has an important role in anxiety. We focused on two brain areas, the amygdala (of importance for the mediation of fear and anxiety) and the dorsal raphe (i.e. the site of origin of major afferent serotonin pathways, including those that project to the amygdala). In these brain areas, we measured serotonergic turnover (using HPLC) and the mRNA expression of a number of serotonin-related genes (using real-time PCR). We found that acute central administration of ghrelin to mice increased the serotonergic turnover in the amygdala. It also increased the mRNA expression of a number of serotonin receptors, both in the amygdala and in the dorsal raphe. Studies in ghrelin receptor (GHS-R1A) knock-out mice showed a decreased mRNA expression of serotonergic receptors in both the amygdala and the dorsal raphe, relative to their wild-type littermates. We conclude that the central serotonin system is a target for ghrelin, providing a candidate neurochemical substrate of importance for ghrelin's effects on mood.


Asunto(s)
Amígdala del Cerebelo/metabolismo , Ghrelina/metabolismo , Núcleos del Rafe/metabolismo , Animales , Expresión Génica , Ácido Hidroxiindolacético/metabolismo , Hipotálamo/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Monoaminooxidasa/metabolismo , ARN Mensajero/metabolismo , Receptores de Ghrelina/genética , Receptores de Ghrelina/metabolismo , Receptores de Serotonina/metabolismo , Serotonina/metabolismo
3.
Neuro Oncol ; 15(11): 1469-78, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24101737

RESUMEN

BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive brain tumor in adults, and despite state-of-the-art treatment, survival remains poor and novel therapeutics are sorely needed. The aim of the present study was to identify new synergistic drug pairs for GBM. In addition, we aimed to explore differences in drug-drug interactions across multiple GBM-derived cell cultures and predict such differences by use of transcriptional biomarkers. METHODS: We performed a screen in which we quantified drug-drug interactions for 465 drug pairs in each of the 5 GBM cell lines U87MG, U343MG, U373MG, A172, and T98G. Selected interactions were further tested using isobole-based analysis and validated in 5 glioma-initiating cell cultures. Furthermore, drug interactions were predicted using microarray-based transcriptional profiling in combination with statistical modeling. RESULTS: Of the 5 × 465 drug pairs, we could define a subset of drug pairs with strong interaction in both standard cell lines and glioma-initiating cell cultures. In particular, a subset of pairs involving the pharmaceutical compounds rimcazole, sertraline, pterostilbene, and gefitinib showed a strong interaction in a majority of the cell cultures tested. Statistical modeling of microarray and interaction data using sparse canonical correlation analysis revealed several predictive biomarkers, which we propose could be of importance in regulating drug pair responses. CONCLUSION: We identify novel candidate drug pairs for GBM and suggest possibilities to prospectively use transcriptional biomarkers to predict drug interactions in individual cases.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Glioblastoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carbazoles/uso terapéutico , Línea Celular Tumoral , Interacciones Farmacológicas , Gefitinib , Humanos , Quinazolinas/uso terapéutico , Sertralina/uso terapéutico , Estilbenos/uso terapéutico
4.
PLoS One ; 7(3): e34313, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22479599

RESUMEN

Mutation of the melanocortin-receptor 4 (MC4R) is the most frequent cause of severe obesity in humans. Binding of agouti-related peptide (AgRP) to MC4R involves the co-receptor syndecan-3, a heparan sulfate proteoglycan. The proteoglycan can be structurally modified by the enzyme heparanase. Here we tested the hypothesis that heparanase plays a role in food intake behaviour and energy balance regulation by analysing body weight, body composition and food intake in genetically modified mice that either lack or overexpress heparanase. We also assessed food intake and body weight following acute central intracerebroventricular administration of heparanase; such treatment reduced food intake in wildtype mice, an effect that was abolished in mice lacking MC4R. By contrast, heparanase knockout mice on a high-fat diet showed increased food intake and maturity-onset obesity, with up to a 40% increase in body fat. Mice overexpressing heparanase displayed essentially the opposite phenotypes, with a reduced fat mass. These results implicate heparanase in energy balance control via the central melanocortin system. Our data indicate that heparanase acts as a negative modulator of AgRP signaling at MC4R, through cleavage of heparan sulfate chains presumably linked to syndecan-3.


Asunto(s)
Proteína Relacionada con Agouti/metabolismo , Ingestión de Alimentos/fisiología , Glucuronidasa/farmacología , Receptor de Melanocortina Tipo 4/genética , Animales , Composición Corporal , Peso Corporal , Cruzamientos Genéticos , Grasas de la Dieta , Ingestión de Alimentos/genética , Metabolismo Energético/genética , Conducta Alimentaria , Femenino , Regulación Enzimológica de la Expresión Génica , Infusiones Intraventriculares , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptor de Melanocortina Tipo 4/metabolismo , Transducción de Señal , Sindecano-3/metabolismo , alfa-MSH/metabolismo
5.
Am J Physiol Cell Physiol ; 297(1): C140-51, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19420002

RESUMEN

The action of interleukin-6 (IL-6) impacts female reproduction. Although IL-6 was recently shown to inhibit cilia activity in human fallopian tubes in vitro, the molecular mechanisms underlying IL-6 signaling to tubal function remain elusive. Here, we investigate the cellular localization, regulation, and possible function of two IL-6 receptors (IL-6R alpha and gp130) in mouse and human fallopian tubes in vivo. We show that IL-6R alpha is restricted to the cilia of epithelial cells in both mouse and human fallopian tubes. Exogenous 17beta-estradiol (E(2)), but not progesterone (P(4)), causes a time-dependent decrease in IL-6R alpha expression, which is blocked by the estrogen receptor (ER) antagonist ICI-182,780. Exposure of different ER-selective agonists propyl-(1H)-pyrazole-1,3,5-triyl-trisphenol or 2,3-bis-(4-hydroxyphenyl)-propionitrile demonstrated an ER subtype-specific regulation of IL-6R alpha in mouse fallopian tubes. In contrast to IL-6R alpha, gp130 was detected in tubal epithelial cells in mice but not in humans. In humans, gp130 was found in the muscle cells and was decreased in the periovulatory and luteal phases during the reproductive cycles, indicating a species-specific expression and regulation of gp130 in the fallopian tube. Expression of tubal IL-6R alpha and gp130 in IL-6 knockout mice was found to be normal; however, E(2) treatment increased IL-6R alpha, but not gp130, in IL-6 knockout mice when compared with wild-type mice. Furthermore, expression levels of IL-6R alpha, but not gp130, decreased in parallel with estrogenic accelerated oocyte-cumulus complex (OCC) transport in mouse fallopian tubes. Our findings open the possibility that cilia-specific IL-6R alpha may play a role in the regulation of OCC transport and suggest an estrogen-regulatory pathway of IL-6R alpha in the fallopian tube.


Asunto(s)
Células Epiteliales/metabolismo , Estradiol/metabolismo , Trompas Uterinas/metabolismo , Interleucina-6/metabolismo , Ovulación , Receptores de Interleucina-6/metabolismo , Transducción de Señal , Adulto , Animales , Cilios/metabolismo , Células del Cúmulo/metabolismo , Receptor gp130 de Citocinas/metabolismo , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo , Células Epiteliales/efectos de los fármacos , Estradiol/administración & dosificación , Moduladores de los Receptores de Estrógeno/farmacología , Receptor alfa de Estrógeno/metabolismo , Trompas Uterinas/efectos de los fármacos , Femenino , Humanos , Inyecciones Intraperitoneales , Interleucina-6/deficiencia , Interleucina-6/genética , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Oocitos/metabolismo , Ovulación/efectos de los fármacos , Progesterona/metabolismo , Transducción de Señal/efectos de los fármacos , Especificidad de la Especie , Factores de Tiempo
6.
Chem Biol ; 16(4): 432-41, 2009 Apr 24.
Artículo en Inglés | MEDLINE | ID: mdl-19389629

RESUMEN

We combined reverse and chemical genetics to identify targets and compounds modulating blood vessel development. Through transcript profiling in mice, we identified 150 potentially druggable microvessel-enriched gene products. Orthologs of 50 of these were knocked down in a reverse genetic screen in zebrafish, demonstrating that 16 were necessary for developmental angiogenesis. In parallel, 1280 pharmacologically active compounds were screened in a human cell-based assay, identifying 28 compounds selectively inhibiting endothelial sprouting. Several links were revealed between the results of the reverse and chemical genetic screens, including the serine/threonine (S/T) phosphatases ppp1ca, ppp1cc, and ppp4c and an inhibitor of this gene family; Endothall. Our results suggest that the combination of reverse and chemical genetic screens, in vertebrates, is an efficient strategy for the identification of drug targets and compounds that modulate complex biological systems, such as angiogenesis.


Asunto(s)
Inhibidores de la Angiogénesis/química , Inhibidores de la Angiogénesis/genética , Neovascularización Fisiológica/efectos de los fármacos , Fosfoproteínas Fosfatasas/genética , Fosfoproteínas Fosfatasas/metabolismo , Inhibidores de la Angiogénesis/metabolismo , Animales , Células Cultivadas , Ácidos Dicarboxílicos/metabolismo , Evaluación Preclínica de Medicamentos , Células Endoteliales/citología , Regulación de la Expresión Génica , Humanos , Ratones , Fosfoproteínas Fosfatasas/antagonistas & inhibidores , Pez Cebra
7.
Biol Reprod ; 80(6): 1262-71, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19211805

RESUMEN

Clomiphene citrate (CC) therapy for disorders of anovulatory infertility has been linked to an increased frequency of tubal ectopic pregnancy. Although CC enhances apoptotic processes in the ovaries, villi, and decidual tissues, its effect on apoptosis in the fallopian tube is unknown. Here, we show that chronic treatment with CC induces tubal apoptosis, but not necrosis, through an intrinsic mitochondria-dependent signaling pathway in vivo. The apoptosis was specific to epithelial cells in the isthmus, and the damage was reversed with 17beta-estradiol (E2); however, pretreatment or concomitant treatment with E2 did not protect against tubal apoptosis induced by chronic treatment with CC. Chronic treatment activated estrogen receptors (ESRs), particularly cilia-localized ESR2A (formerly ERbeta2). In contrast to E2, acute treatment of superovulating rats with a high dose of CC or the ESR2-selective agonist 2,3-bis (4-hydroxyphenyl)-propionitrile (DPN) significantly delayed the transport of oocyte-cumulus complexes through the fallopian tube. Our findings suggest that in response to chronic CC therapy, isthmus-specific apoptosis of epithelial cells and activation of cilia-ESR2A act in parallel to block gamete and embryo passage through the fallopian tube, eventually resulting in tubal ectopic pregnancy.


Asunto(s)
Apoptosis/efectos de los fármacos , Clomifeno/administración & dosificación , Trompas Uterinas/efectos de los fármacos , Moduladores Selectivos de los Receptores de Estrógeno/administración & dosificación , Animales , Peso Corporal/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Clomifeno/efectos adversos , Células Epiteliales/efectos de los fármacos , Estradiol/farmacología , Trompas Uterinas/citología , Trompas Uterinas/metabolismo , Trompas Uterinas/patología , Femenino , Hormonas Esteroides Gonadales/sangre , Oocitos/efectos de los fármacos , Tamaño de los Órganos/efectos de los fármacos , Embarazo , Embarazo Tubario/inducido químicamente , Ratas , Ratas Sprague-Dawley , Receptores de Estrógenos/metabolismo , Moduladores Selectivos de los Receptores de Estrógeno/efectos adversos , Superovulación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...